478 related articles for article (PubMed ID: 33059715)
21. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
Pelaia C; Pelaia G; Crimi C; Maglio A; Gallelli L; Terracciano R; Vatrella A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922072
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
Ly N; Zheng Y; Griffiths JM; van der Merwe R; Agoram B; Parnes JR; Roskos L
J Clin Pharmacol; 2021 Jul; 61(7):901-912. PubMed ID: 33368307
[TBL] [Abstract][Full Text] [Related]
23. Tezepelumab for asthma.
Nolasco S; Pelaia C; Scioscia G; Campisi R; Crimi C
Drugs Today (Barc); 2022 Dec; 58(12):591-603. PubMed ID: 36651067
[TBL] [Abstract][Full Text] [Related]
24. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
Corren J; Pham TH; Garcia Gil E; Sałapa K; Ren P; Parnes JR; Colice G; Griffiths JM
Allergy; 2022 Jun; 77(6):1786-1796. PubMed ID: 34913186
[TBL] [Abstract][Full Text] [Related]
25. Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.
Bagnasco D; De Ferrari L; Bondi B; Candeliere MG; Mincarini M; Riccio AM; Braido F
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892164
[TBL] [Abstract][Full Text] [Related]
26. Targeting TSLP in Asthma.
Parnes JR; Molfino NA; Colice G; Martin U; Corren J; Menzies-Gow A
J Asthma Allergy; 2022; 15():749-765. PubMed ID: 35685846
[TBL] [Abstract][Full Text] [Related]
27. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma.
Matera MG; Ora J; Rogliani P; Cazzola M
Expert Opin Drug Discov; 2023; 18(9):951-963. PubMed ID: 37387523
[TBL] [Abstract][Full Text] [Related]
28. Tezepelumab: patient selection and place in therapy in severe asthma.
Menzella F; Munari S; Corsi L; Tonin S; Cestaro W; Ballarin A; Floriani A; Dartora C; Senna G
J Int Med Res; 2024 Apr; 52(4):3000605241246740. PubMed ID: 38676539
[TBL] [Abstract][Full Text] [Related]
29. [Tezepelumab (Tezspire®) : new biological treatment of severe asthma].
Schleich F; Sabbe M; Moermans C; Louis R
Rev Med Liege; 2024 Jan; 79(1):60-64. PubMed ID: 38223972
[TBL] [Abstract][Full Text] [Related]
30. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR).
Pavord ID; Hoyte FCL; Lindsley AW; Ambrose CS; Spahn JD; Roseti SL; Cook B; Griffiths JM; Hellqvist Å; Martin N; Llanos JP; Martin N; Colice G; Corren J
Ann Allergy Asthma Immunol; 2023 Nov; 131(5):587-597.e3. PubMed ID: 37619779
[TBL] [Abstract][Full Text] [Related]
31. Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date.
Dorey-Stein ZL; Shenoy KV
Drug Des Devel Ther; 2021; 15():331-338. PubMed ID: 33536746
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy.
Corren J; Ambrose CS; Sałapa K; Roseti SL; Griffiths JM; Parnes JR; Colice G
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4334-4342.e6. PubMed ID: 34358701
[TBL] [Abstract][Full Text] [Related]
33. [Mechanism of action of tezepelumab (TEZSPIRE
Niu M; Yabuta T; Makita N
Nihon Yakurigaku Zasshi; 2024; 159(1):53-60. PubMed ID: 38171840
[TBL] [Abstract][Full Text] [Related]
34. Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma.
Salvati L; Maggi L; Annunziato F; Cosmi L
Curr Opin Allergy Clin Immunol; 2021 Dec; 21(6):590-596. PubMed ID: 34608100
[TBL] [Abstract][Full Text] [Related]
35. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.
Corren J; Ambrose CS; Griffiths JM; Hellqvist Å; Lindsley AW; Llanos JP; Colice G; Menzies-Gow A
Clin Exp Allergy; 2023 Apr; 53(4):417-428. PubMed ID: 36507576
[TBL] [Abstract][Full Text] [Related]
37. Real-life experience after 3 months with tezepelumab before marketing approval.
Violán VV; Cano BG; Casero MÁR; González-Mancebo E; Vicente EM; Trujillo MJT; Gandolfo-Cano M
Allergol Immunopathol (Madr); 2024; 52(2):80-82. PubMed ID: 38459894
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma.
Plaza V; Cañete C; Domingo C; Martínez Rivera C; Muñoz X
Open Respir Arch; 2023; 5(2):100231. PubMed ID: 37496871
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of tezepelumab in patients recruited in Japan who participated in the phase 3 NAVIGATOR study.
Ishizuka T; Menzies-Gow A; Okada H; Fukushima Y; Hayashi N; Colice G; Ponnarambil S; Hunter G; Odajima H; Ebisawa M
Allergol Int; 2023 Jan; 72(1):82-88. PubMed ID: 35977863
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
Wechsler ME; Menzies-Gow A; Brightling CE; Kuna P; Korn S; Welte T; Griffiths JM; Sałapa K; Hellqvist Å; Almqvist G; Lal H; Kaur P; Skärby T; Colice G;
Lancet Respir Med; 2022 Jul; 10(7):650-660. PubMed ID: 35364018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
